Anupam Rasayan India Ltd reported a landmark fiscal year 2026 with record annual sales. The company achieved a total revenue of Rs 23,836 Mn, a 65% year-on-year growth. Profit After Tax rose to Rs 2,222 Mn, marking a 39% increase. The performance was bolstered by robust operational execution, the integration of Jayhawk Fine Chemicals, and the signing of a definitive agreement to acquire Bliss GVS Pharma to expand pharmaceutical value chain capabilities.
Financial Performance for FY26
Anupam Rasayan has concluded a transformative fiscal year 2026. The company recorded an annual revenue of Rs 23,836 Mn, representing a substantial 65% growth compared to the previous year. EBITDA for the year stood at Rs 5,430 Mn, an increase of 32%, resulting in an EBITDA margin of 23%. The annual Profit After Tax (PAT) reached Rs 2,222 Mn, showcasing a strong 39% rise over the Rs 1,600 Mn reported in FY25.
Quarterly Highlights
During the final quarter (January-March 2026), the company generated Rs 6,392 Mn in revenue, reflecting a 26% growth compared to the same period in the previous fiscal year. While EBITDA for the quarter was recorded at Rs 1,407 Mn, the company continues to focus on long-term value creation through its niche and complex chemical manufacturing capabilities.
Strategic Acquisitions and Growth Outlook
The company achieved a key strategic milestone with the successful integration of Jayhawk Fine Chemicals in the United States, which generated US$ 95 Mn in proforma revenue. This acquisition has significantly strengthened the company’s global footprint and access to innovator customers in North America. Furthermore, the company has entered into a definitive agreement to acquire Bliss GVS Pharma. This move is expected to create meaningful synergies, enhancing the company’s pharmaceutical value chain and diversified product portfolio.
Looking ahead, Anupam Rasayan remains well-positioned for sustained growth, supported by a strong product pipeline and increasing contributions from its Performance Materials and Pharma segments.
Source: BSE
